Qici Sanling decoction suppresses bladder cancer growth by inhibiting the Wnt/Β-catenin pathway

Context: Bladder cancer, which has high recurrence, is one of the most deadly cancers in the world. Astragalus propinquus Schischkin (Fabaceae) and Sagittaria sagittifolia L. (Alismataceae) are important herbs reported to be effective in cancer therapy. Objective: The efficacy of QCSL (Qici Sanling...

Full description

Saved in:
Bibliographic Details
Main Authors: Hua Gong (Author), Weihua Chen (Author), Lanhua Mi (Author), Dan Wang (Author), Youkang Zhao (Author), Chao Yu (Author), Aiguang Zhao (Author)
Format: Book
Published: Taylor & Francis Group, 2019-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_570dc6ab2ea84956bf7c47b24e38f4e6
042 |a dc 
100 1 0 |a Hua Gong  |e author 
700 1 0 |a Weihua Chen  |e author 
700 1 0 |a Lanhua Mi  |e author 
700 1 0 |a Dan Wang  |e author 
700 1 0 |a Youkang Zhao  |e author 
700 1 0 |a Chao Yu  |e author 
700 1 0 |a Aiguang Zhao  |e author 
245 0 0 |a Qici Sanling decoction suppresses bladder cancer growth by inhibiting the Wnt/Β-catenin pathway 
260 |b Taylor & Francis Group,   |c 2019-01-01T00:00:00Z. 
500 |a 1388-0209 
500 |a 1744-5116 
500 |a 10.1080/13880209.2019.1626449 
520 |a Context: Bladder cancer, which has high recurrence, is one of the most deadly cancers in the world. Astragalus propinquus Schischkin (Fabaceae) and Sagittaria sagittifolia L. (Alismataceae) are important herbs reported to be effective in cancer therapy. Objective: The efficacy of QCSL (Qici Sanling decoction) in bladder cancer treatment was examined. Materials and methods: T24 cells were injected into the flanks of nude mice and the mice were randomly divided into five groups: control; 20 mg/kg XAV-939 (an inhibitor of the WNT/β-catenin pathway); QCSL (100, 200, or 400 mg/kg). After 7 weeks, the mice were anaesthetised using isoflurane and the xenografts were excised to perform further experiments. Results: Both XAV-939 (tumour volume: 379.67 ± 159.92 mm3) and QCSL (796.18 ± 101.6 mm3) dramatically suppressed tumour growth comparing with control group (3612.12 ± 575.03 mm3). XAV-939 and QCSL treatments decreased cell proliferation from 56.3 ± 0.05% to 29.02 ± 0.07% and 37.51 ± 0.04%, respectively. In agreement, more infiltration of immune cells and pyknotic cells upon XAV-939 (apoptosis rates: 43.92 ± 0.03%) and QCSL (34.57 ± 0.04%) treatment comparing with control group (15.59 ± 0.03%) were observed. Furthermore, TUNEL staining of xenograft tumours illustrated more apoptotic cells upon XAV-939 and QCSL treatment. Mechanistically, XAV-939 and QCSL treatments significantly inhibited WNT/β-catenin pathway in T24 xenograft tumours. Discussion and conclusions: Our findings give new insights into the role of QCSL in bladder cancer and explore potential mechanisms contributing to the therapeutic effects of QCSL in bladder cancer. 
546 |a EN 
690 |a qcsl 
690 |a tcm 
690 |a xav-939 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Pharmaceutical Biology, Vol 57, Iss 1, Pp 507-513 (2019) 
787 0 |n http://dx.doi.org/10.1080/13880209.2019.1626449 
787 0 |n https://doaj.org/toc/1388-0209 
787 0 |n https://doaj.org/toc/1744-5116 
856 4 1 |u https://doaj.org/article/570dc6ab2ea84956bf7c47b24e38f4e6  |z Connect to this object online.